학술논문
Tepotinib + osimertinib for EGFR mutant (EGFR m) NSCLC with MET amplification (MET amp) after first-line (1L) osimertinib.
Document Type
Article
Author
Tan, Daniel Shao-Weng; Kim, Tae Min; Guarneri, Valentina; VOON, PEI JYE; Lim, Boon Khaw; Wislez, Marie; Huang, Cheng; Liam, Chong Kin; Mazieres, Julien; Tho, Lye Mun; Hayashi, Hidetoshi; Nhung, Nguyen; Chia, Puey Ling; de Marinis, Filippo; Le, Xiuning; Karachaliou, Niki; Brutlach, Sabine; Adrian, Svenja; Ellers-Lenz, Barbara; Wu, Yi-Long
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p9021-9021, 1p
Subject
Language
ISSN
0732183X